ZENBEXUS™ REMS | Change in Reproductive Potential Status Form

Prescribers certified in ZENBEXUS REMS (Risk Evaluation and Mitigation Strategy) must use this form to report a change in reproductive potential status for enrolled patients within 10 business days of awareness. Complete and submit:

- **Online** at www.BMSREMSPatientSafety.com **or**
- **Email** to REMSContactCenter@bms.com **or**
- **Fax** to 1-877-296-1932

Patient Information *(Fields marked * are REQUIRED.)*

*First Name (Legal):	*Last Name (Legal):	
*Date of Birth (MM/DD/YYYY):		
*Address Line #1:		
Address Line #2:		
*City:	*State:	*ZIP Code:
*Phone Number:		

Prescriber (HCP) Information

*First Name:	*Last Name:
*National Provider Identifier (NPI):	

Continued on Next Page

ZENBEXUS™ REMS | Change in Reproductive Potential Status Form

Definitions of Reproductive Potential Status

Females Who Can Become Pregnant

- Biologically female sex with a uterus and at least one ovary, who is at least Tanner Stage 3 or entered puberty and has not completed menopause†

Females Who Cannot Become Pregnant

- Biologically female sex who has undergone a hysterectomy or a bilateral oophorectomy, not gone through menarche or reached Tanner Stage 3, or completed menopause

†**Menopause:** Defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.

Report a Change in Reproductive Potential Status *(Select one.)*

Based on the definitions provided above, the patient's reproductive potential status has changed to a:

◯ **Female Who CANNOT Become Pregnant**

- Reasons for change in status:
  - ☐ Menopause
  - ☐ Medical/surgical (specify) _____
  - ☐ Previous misclassification
  - ☐ Other (specify) _____

◯ **Female Who CAN Become Pregnant**

- Reasons for change in status:
  - ☐ Reached Tanner Stage 3 or entered puberty
  - ☐ Previous misclassification
  - ☐ Other (specify) _____

By signing, I hereby certify that the patient's reproductive potential status is accurately reported.

*Prescriber (HCP) Signature:	*Date:

Suspected pregnancies should be reported to the REMS Call Center at 1-888-423-5436. Report all other suspected adverse events or product quality complaints associated with ZENBEXUS™ (iberdomide) to the REMS Call Center at 1-888-423-5436 or the FDA at 1-800-FDA-1088 or online at www.fda.gov/medwatch.

For more information, call the REMS Call Center at 1-888-423-5436.

Bristol Myers Squibb®

© 2026 Bristol-Myers Squibb Company

2070-US-2600391 08/26